JP2022527334A - 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 - Google Patents

腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 Download PDF

Info

Publication number
JP2022527334A
JP2022527334A JP2021558768A JP2021558768A JP2022527334A JP 2022527334 A JP2022527334 A JP 2022527334A JP 2021558768 A JP2021558768 A JP 2021558768A JP 2021558768 A JP2021558768 A JP 2021558768A JP 2022527334 A JP2022527334 A JP 2022527334A
Authority
JP
Japan
Prior art keywords
administered
antigen
binding fragment
olecurumab
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021558768A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020202038A5 (https=
JP2022527334A5 (https=
Inventor
クマール，ラケシュ
クーパー，ザッカリー
カーン，アニス
エングラート，ジャドソン
キャスリン ミュラー，ナンシー
フェルテ，シャルル
ロドリゲス，パブロ マルティネス
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2022527334A publication Critical patent/JP2022527334A/ja
Publication of JPWO2020202038A5 publication Critical patent/JPWO2020202038A5/ja
Publication of JP2022527334A5 publication Critical patent/JP2022527334A5/ja
Priority to JP2025166226A priority Critical patent/JP2026031542A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021558768A 2019-04-02 2020-04-01 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 Pending JP2022527334A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025166226A JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962828177P 2019-04-02 2019-04-02
US62/828,177 2019-04-02
PCT/IB2020/053110 WO2020202038A1 (en) 2019-04-02 2020-04-01 Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025166226A Division JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法

Publications (3)

Publication Number Publication Date
JP2022527334A true JP2022527334A (ja) 2022-06-01
JPWO2020202038A5 JPWO2020202038A5 (https=) 2023-11-08
JP2022527334A5 JP2022527334A5 (https=) 2023-11-08

Family

ID=72663659

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021558768A Pending JP2022527334A (ja) 2019-04-02 2020-04-01 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法
JP2025166226A Pending JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025166226A Pending JP2026031542A (ja) 2019-04-02 2025-10-02 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法

Country Status (13)

Country Link
US (1) US20200317803A1 (https=)
EP (1) EP3947447A4 (https=)
JP (2) JP2022527334A (https=)
KR (1) KR20210148253A (https=)
CN (2) CN113993890A (https=)
AU (2) AU2020254100B9 (https=)
CA (1) CA3134671A1 (https=)
EA (1) EA202192587A1 (https=)
IL (1) IL286504A (https=)
MA (1) MA55558A (https=)
SG (1) SG11202110694RA (https=)
TW (1) TW202102545A (https=)
WO (1) WO2020202038A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542523A (ja) * 2020-09-23 2023-10-10 メディミューン，エルエルシー 抗ｃｄ７３及び抗ｐｄ－ｌ１抗体並びに化学療法を使用する治療方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2023227115A1 (en) * 2022-05-26 2023-11-30 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
EP4626552A1 (en) * 2022-12-01 2025-10-08 MedImmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501197A (ja) * 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
KR20230038311A (ko) * 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
CN118307674A (zh) * 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501197A (ja) * 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) (ClinicalTrials.g", [ONLINE], JPN6024047999, March 2019 (2019-03-01), ISSN: 0005608446 *
HISTORY OF CHANGES FOR STUDY: NCT03611556, CLINICALTRIALS.GOV ARCHIVE, [ONLINE], JPN6024020014, 21 March 2019 (2019-03-21), ISSN: 0005474376 *
HISTORY OF CHANGES FOR STUDY: NCT03616886, CLINICALTRIALS.GOV ARCHIVE, [ONLINE], JPN6024020013, 23 January 2019 (2019-01-23), ISSN: 0005474375 *
LIMAGNE, E. ET AL.: "Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Effic", CANCER RESEARCH, vol. 76, no. 18, JPN6024020012, 2016, pages 5241 - 5252, ISSN: 0005474377 *
OVERMAN, M. J. ET AL.: "Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durv", JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.36, No.15 suppl., JPN6024020010, 2018, ISSN: 0005474373 *
SCHMID, P. ET AL.: "BEGONIA: Phase Ib/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and", CANCER RESEARCH, vol. Vol.79, No.4 suppl., JPN6024020011, 15 February 2019 (2019-02-15), ISSN: 0005474374 *
時任 高章，東 公一: "分子標的薬の最適な治療シーケンス 非小細胞肺がん III期非小細胞肺がんに対する化学放射線療法における", がん分子標的治療, vol. 第16巻，第4号, JPN6024048000, February 2019 (2019-02-01), pages 342 - 346, ISSN: 0005608447 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542523A (ja) * 2020-09-23 2023-10-10 メディミューン，エルエルシー 抗ｃｄ７３及び抗ｐｄ－ｌ１抗体並びに化学療法を使用する治療方法

Also Published As

Publication number Publication date
KR20210148253A (ko) 2021-12-07
EP3947447A1 (en) 2022-02-09
AU2025200063A1 (en) 2025-01-30
AU2020254100B2 (en) 2024-10-10
CN113993890A (zh) 2022-01-28
US20200317803A1 (en) 2020-10-08
SG11202110694RA (en) 2021-10-28
EA202192587A1 (ru) 2022-01-13
AU2020254100A1 (en) 2021-11-18
TW202102545A (zh) 2021-01-16
JP2026031542A (ja) 2026-02-24
CN119857140A (zh) 2025-04-22
MA55558A (fr) 2022-02-09
AU2020254100B9 (en) 2024-11-21
WO2020202038A1 (en) 2020-10-08
CA3134671A1 (en) 2020-10-08
IL286504A (en) 2021-10-31
EP3947447A4 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
US11866509B2 (en) Humanized antibodies against CEACAM1
JP2022527334A (ja) 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法
KR20170074962A (ko) 암에 대한 조합 요법
CN108350081A (zh) 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
TW201811369A (zh) Mek抑制劑、pd-1軸抑制劑及vegf抑制劑之組合療法
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
HK40118859A (zh) 用於治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
EA047051B1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
RU2806210C2 (ru) Антитела к b7-h1 и к ctla-4 для лечения немелкоклеточного рака легкого
HK1235023B (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
HK1235023A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603